Drug Trial Radar · NCT02531126
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
877
Actual
Start
Dec 2, 2015
Primary completion
Dec 19, 2024
Study completion Dec 19, 2024
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis. Only those participants who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be eligible.
Conditions
- Ulcerative Colitis
Interventions
RPC1063Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs)Time frame: From first dose to 90 days post last dose (Up to approximately 92 months)
Locations
41 sites in 20 countries. Site status is shown where the registry gives one.
Local Institution - 144
Tucson, Arizona
Local Institution - 102
Anaheim, California
Local Institution - 117
Mission Hills, California
Local Institution - 112
Oak Lawn, Illinois
Local Institution - 119
Baton Rouge, Louisiana
Local Institution - 127
Jacksonville, North Carolina
Local Institution - 290
Oklahoma City, Oklahoma
Local Institution - 143
Portland, Oregon
Local Institution - 179
Germantown, Tennessee
Local Institution - 122
Dallas, Texas
Local Institution - 152
Camperdown, New South Wales, Australia
Local Institution - 751
Vitebsk, Belarus
Local Institution - 600
Ghent, Belgium
Local Institution - 601
Leuven, Belgium
Local Institution - 450
Sofia, Bulgaria
Local Institution - 459
Sofia, Bulgaria
Local Institution - 451
Sofia, Bulgaria
Local Institution - 264
Lindsay, Ontario, Canada
Local Institution - 611
Osijek, Croatia
Local Institution - 342
Klatovy, Czechia
Local Institution - 337
Prague, Czechia
Local Institution - 535
Berlin, Germany
Local Institution - 525
Berlin, Germany
Local Institution - 545
Frankfurt, Germany
Local Institution - 643
Athens, Greece
Local Institution - 816
Balatonfüred, Hungary
Local Institution - 808
Debrecen, Hungary
Local Institution - 505
Rehovot, Israel
Local Institution - 567
Florence, Tuscany, Italy
Local Institution - 658
Chisinau, Moldova
Local Institution - 659
Chisinau, Moldova
Local Institution - 425
Kłodzko, Poland
Local Institution - 677
Bucharest, Romania
Local Institution - 673
Bucharest, Romania
Local Institution - 910
Bardejov, Slovakia
Local Institution - 364
Seongnam-si, South Korea
Local Institution - 354
Wŏnju, South Korea
Local Institution - 954
Kharkiv, Ukraine
Local Institution - 957
Vinnytsia, Ukraine
Local Institution - 243
London, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.